AFT Launches Petition Condemning EpiPen Price Gouging by Mylan Corp.
In the United States, 3.6 million people have an EpiPen prescription to treat severe allergic reactions.
Since John Paulson invested $1 billion in Mylan Pharmaceuticals, making him one of its biggest investors, the price of this crucial drug has spiked—by 32 percent over the past year and by a whopping 450 percent since 2007. As hedge funds and Mylan make profits, most families and schools simply can’t afford to pay $600 apiece for an EpiPen.